Full-Time

Senior Field Service Engineer

Cellanome

Cellanome

51-200 employees

Automated platform for live single-cell assays

Compensation Overview

$120k - $170k/yr

+ Equity

Foster City, CA, USA + 1 more

More locations: San Diego, CA, USA

In Person

Travel up to 50% of working time, including occasional overnight and weekend travel.

Bachelor's, Master's

Category
Hardware Engineering (1)
Required Skills
CRM
Salesforce

Get referred to Cellanome

See people who can refer or advise you

Requirements
  • A Bachelor's or other advanced university degree in engineering, life sciences, or a related field.
  • At least 5 years of field service experience, ideally with complex life science tools or instruments.
  • Strong problem-solving skills and attention to detail.
  • Ability to understand customer needs, objectives, and decision-making processes to drive customer satisfaction.
  • Ability to work in a cross-functional, collaborative, high-growth environment.
  • A valid passport with at least 90 days of validity and a driver's license.
  • Ability to perform the essential duties with or without reasonable accommodations.
  • Ability to lift up to 50 pounds for approximately 15% of the typical working day.
  • Ability to work in front of a computer screen for approximately 90% of the typical working day; grasp with both hands, pinch with the thumb and forefinger, turn with the hand or arm, and reach above shoulder height.
  • Ability to comply with personal protective equipment requirements.
  • Ability to travel up to 50% of working time, including overnight and weekend travel at times.
Responsibilities
  • Travel to customer and collaborator sites to provide technical support, including troubleshooting, design evaluation, problem-solving, and repair.
  • Conduct customer site inspections for instrument receipt, installation, and relocations.
  • Ensure compliance with instrument specifications and warranty commitments.
  • Maintain and document completed work in service reports.
  • Provide requirements and feedback to improve product reliability, serviceability, and design.
  • Perform verification testing and preventive maintenance for the external instrument fleet.
  • Help maintain and service the internal instrument fleet as time allows and provide feedback to Research and Product Development teams.
  • Support new product introductions and deployment of product improvements in the field.
  • Partner with a Field Application Scientist to provide technical support and ensure optimal product use and customer or collaborator satisfaction.
Desired Qualifications
  • Experience in an early-stage company.
  • Experience with Salesforce and MasterControl or a similar customer relationship management and document control system.
  • Hands-on experience with instrumentation and laboratory equipment, including experience as an end user of related instrumentation.
  • Knowledge of cellular biology.

Cellanome provides an automated platform for live-cell phenotypic and functional assays that analyze single cells at scale. It runs high-throughput experiments that integrate with existing lab workflows, collecting multi-parameter data and allowing iterative testing under different conditions. The system emphasizes single-cell granularity, scalable data collection, and easy assay customization without major process changes. Its goal is to help life sciences, medical research, pharmaceutical, and biotech teams gain deeper cellular insights to accelerate discovery through a platform-as-a-service model.

Company Size

51-200

Company Stage

Series C

Total Funding

$276.9M

Headquarters

Foster City, California

Founded

2020

Get referred to Cellanome

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Psomagen added the R3200 on March 26, 2026, validating external demand.
  • Cellanome showcased live-cell analysis marrying imaging and sequencing at AGBT 2026.
  • Cellanome raised $75.9 million on June 22, 2026, extending runway.

What critics are saying

  • 10x Genomics and other single-cell vendors already dominate adjacent workflows.
  • Cellanome still lacks proof of broad customer adoption beyond Psomagen and conferences.
  • If 2026 spending misses hardware sales, the platform becomes an expensive science project.

What makes Cellanome unique

  • Cellanome links longitudinal live-cell imaging to single-cell transcriptomics from the same cells.
  • Its CellCage micro-3D-printed enclosures isolate cells while drugs and antibodies flow.
  • R3200 captures morphology, phenotype, and RNA on identical live cells.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Stock Options

401(k) Retirement Plan

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

58%

2 year growth

0%
U.S. Securities and Exchange Commission
Jul 17th, 2026
EDGAR Filing Documents for 0000905148-26-003005

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231Type: D | Act: 33 | File No.: 021-588010 | Film No.: 261104659

Intelligence360 News
Jul 17th, 2026
Cellanome files to raise $75.9M for live-cell imaging and single-cell transcriptomics platform

Cellanome has filed a notice with the US Securities and Exchange Commission to raise up to $75.9 million in new funding. The filing was made under Regulation D of the Securities Act of 1933, which allows companies to sell securities without full registration. The company develops technologies that combine longitudinal live-cell imaging with single-cell transcriptomics from the same cells. This approach enables scientists to capture cellular dynamics over time and connect cellular behaviour with molecular state. Researchers can access Cellanome's technology by implementing its R3200 platform in their laboratories, using its assay services, or collaborating with the company's scientists on new applications.

The Business Journals
Jan 30th, 2024
Peninsula startup with Illumina roots lands $150 million to peer deeper into cells

A Peninsula startup launched by top former Illumina execs raises $150 million to help researchers see what happens when cells dance with each other.

The Business Journals
Dec 8th, 2021
Former Illumina execs, Grail co-founder raise $21M for biotech startup

Biotech A-listers have come together to launch a new venture. What's it targeting? They're not saying.